CONCLUSION:
Our Cohort of MIS-N is the largest reported as per current literature data. MIS-N occurs as a syndrome which occurs post-exposure to SARS-CoV2, manifests with a variety of clinical symptoms. The diagnosis of MIS-N can be challenging and needs a high index of suspicion, after all other potential etiologies have been excluded. MIS-N can be considered in a neonate presenting with two or more systems involvement, in the presence of SARS-CoV2 antibodies, along with elevated inflammatory markers. In such cases neonatologists should perform specific investigations such as SARS-CoV2 antigen and antibodies, inflammatory markers routinely along with cardiac biomarkers like Pro BNP, LDH, and early ECHO screening to evaluate myocardial dysfunction when needed. Immunomodulator therapy should be given only for severe cases where definitive criteria of MIS-N are met.